Clinical Trial Update: Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating Teclistamab in patients with recurrent or refractory plasmablastic lymphoma; the trial status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmablastic Lymphoma

Drugs mentioned

• Teclistamab (teclistamab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING